Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681040 · ClinicalTrials.gov registry record
Risk Stratification of COVID-19 Using Urine Biomarkers
A clinical trial of Covid19 and Biomarker, sponsored by National Center for Global Health and Medicine, Japan.
- Active
- Registry status
- 964
- Enrollment target
- 7
- Study locations
NCT04681040 is a study of Covid19 and Biomarker that is active but no longer recruiting, run by National Center for Global Health and Medicine, Japan. The registered enrollment target is 964 participants, below the 2,692-participant average among 94 other Covid19 trials with a reported enrollment target (64% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT04681040, a study of Covid19 and Biomarker, is active but no longer recruiting, sponsored by National Center for Global Health and Medicine, Japan.
- ACTIVE NOT RECRUITING
- Registry status
- 964 participants
- Enrollment target
- 7
- Study locations
Study Summary
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows for rapid and appropriate intervention, including admission to intensive care unit and intensive care therapy, such as mechanical ventilation. A current problem is that only limited data exist predicting the clinical course of COVID-19. This study will determine whether non-invasive urinalysis is useful in assessing and predicting the severity or clinical course of patients with COVID-19.
Conditions Studied
Study Locations (7)
Other
- Danish National Biobank - Copenhagen
- Unilab Group - Manila
Maryland
- MD Mount Sinai - Baltimore
São Paulo
- Hospital das Clinicas Ribeirao Preto - Ribeirão Preto
Kanagawa
- Shonan General Hospital - Kamakura
Tokyo
- National Center Global Health and Medicine - Shinjuku
Yamanashi
- Yamanashi Prefectural Central Hospital - Kofu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2024-03-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681040
The ClinicalTrials.gov registry entry for NCT04681040 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 964 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,692-participant average among 94 other Covid19 trials with a reported enrollment target (64% lower). The listed sponsor is National Center for Global Health and Medicine, Japan, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Covid19 appearing as the primary indexed condition, and to 0 interventions.
NCT04681040 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, Maryland, São Paulo.
Frequently Asked Questions
What is clinical trial NCT04681040 about?
NCT04681040 is a clinical study titled "Risk Stratification of COVID-19 Using Urine Biomarkers". Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows...
What is the current status of trial NCT04681040?
This trial is currently active not recruiting. The enrollment target is 964 participants. The study started on 2020-09-15. Estimated completion is 2024-03-25.
What conditions does trial NCT04681040 study?
This clinical trial studies the following conditions: Covid19, Biomarker, Urine, Acute Respiratory Failure With Hypoxia.
Who is sponsoring clinical trial NCT04681040?
This trial is sponsored by National Center for Global Health and Medicine, Japan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04681040 being conducted?
This trial has 7 study locations across Maryland, São Paulo, Kanagawa, Tokyo, Yamanashi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
COVID-19 Vaccines International Pregnancy Exposure Registry
RECRUITING
-
COVID-19 Survivorship Registry
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Conversations You Want About Corona Virus Disease (COVID-19)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.